168 related articles for article (PubMed ID: 6096607)
41. Development and pharmacology of angiotensin converting enzyme inhibitors.
Antonaccio MJ
J Pharmacol; 1983; 14 Suppl 3():29-45. PubMed ID: 6323887
[TBL] [Abstract][Full Text] [Related]
42. [Effects of angiotensin I converting enzyme inhibitor (captopril) on blood pressure, pulse rate, plasma renin activity, and plasma aldosterone concentration in patients with essential hypertension and normal subjects].
Seto S; Kaku T; Shinagawa T; Matsumoto Y; Doi Y; Tasaki S; Murayama M; Aoi W; Kuramochi M; Hashiba K
Nihon Naika Gakkai Zasshi; 1980 Nov; 69(11):1439-46. PubMed ID: 7017040
[No Abstract] [Full Text] [Related]
43. Comparison of the immediate hemodynamic effects of SQ 14225 (Captopril) and [Sar1, Ileu8] angiotensin II in patients with dialysis resistant hypertension.
Iseki K; Onoyama K; Fujimi S; Fukiyama K; Omae T
Clin Nephrol; 1982 Mar; 17(3):149-54. PubMed ID: 7039897
[TBL] [Abstract][Full Text] [Related]
44. Effects of sodium loading on antihypertensive responses to an angiotensin-converting enzyme inhibitor in spontaneously hypertensive and renal hypertensive rats.
Nakata K; Takada T; Yamauchi H; Iso T
Eur J Pharmacol; 1986 Feb; 121(2):293-5. PubMed ID: 3009208
[TBL] [Abstract][Full Text] [Related]
45. Overview: the role of angiotensin-converting enzyme inhibitors in cardiovascular therapy.
Abrams WB; Davies RO; Ferguson RK
Fed Proc; 1984 Apr; 43(5):1314-21. PubMed ID: 6323221
[TBL] [Abstract][Full Text] [Related]
46. Contrasting effects of the renin-angiotensin system on renal function disclosed during converting enzyme inhibition in patients with renal hypertension.
Rasmussen S; Ibsen H; Giese J
Scand J Urol Nephrol Suppl; 1984; 79():49-52. PubMed ID: 6089319
[TBL] [Abstract][Full Text] [Related]
47. The renin-angiotensin system in aminoglycoside-induced acute renal failure.
Luft FC; Aronoff GR; Evan AP; Connors BA; Weinberger MH; Kleit SA
J Pharmacol Exp Ther; 1982 Feb; 220(2):433-9. PubMed ID: 6276536
[TBL] [Abstract][Full Text] [Related]
48. [Age dependence of the response of blood pressure, heart rate and plasma renin activity to captopril in essential hypertension].
Stanek B; Silberbauer K
Acta Med Austriaca; 1984; 11(3-4):101-5. PubMed ID: 6089491
[TBL] [Abstract][Full Text] [Related]
49. Angiotensin-converting enzyme inhibitors: pathogenic and therapeutic implications for arterial hypertension.
Waeber B; Brunner HR; Wauters JP; Gavras H
Adv Nephrol Necker Hosp; 1981; 10():111-33. PubMed ID: 6267906
[No Abstract] [Full Text] [Related]
50. Effects of angiotensin converting enzyme inhibitor (SA-446) on regional hemodynamics in renal and spontaneously hypertensive rats.
Abe Y; Sakamoto W; Fukui K; Iwao H; Takada T; Yamamoto K
Arch Int Pharmacodyn Ther; 1988; 292():237-47. PubMed ID: 3395170
[TBL] [Abstract][Full Text] [Related]
51. Effects of angiotensin I-converting enzyme inhibitor (SA-446) on renal function in dogs.
Takada T; Yamamoto K; Fujioka S; Tamaki T; Fukui K; Abe Y
Jpn J Pharmacol; 1985 Jun; 38(2):227-30. PubMed ID: 2993720
[TBL] [Abstract][Full Text] [Related]
52. [Antinephritic effect of SA-446, an angiotensin I converting enzyme inhibitor, on crescentic-type anti-GBM nephritis in rats].
Suzuki Y; Ito M; Yamada H; Saitho N; Tsukushi Y
Nihon Jinzo Gakkai Shi; 1985 Nov; 27(11):1485-93. PubMed ID: 3007819
[No Abstract] [Full Text] [Related]
53. Acute and chronic effects of captopril on the renin-angiotensin and kallikrein-kinin systems affecting blood pressure and natriuresis.
Kida O
Nihon Jinzo Gakkai Shi; 1985 Mar; 27(3):343-52. PubMed ID: 3894731
[No Abstract] [Full Text] [Related]
54. Clinical improvement and hormonal changes in severe cardiac failure after captopril treatment.
McGrath BP; Denham IM; Johnston CI
Aust N Z J Med; 1981 Dec; 11(6):639-44. PubMed ID: 6277291
[No Abstract] [Full Text] [Related]
55. [Effect of angiotensin I converting enzyme inhibitor (captopril) on blood pressure and bradykinin in patients with excessive aldosterone secretion].
Haruyama K; Mizuno K; Yamazaki M; Toki T; Yaginuma K; Fukuchi S
Nihon Jinzo Gakkai Shi; 1984 Apr; 26(4):437-44. PubMed ID: 6381834
[No Abstract] [Full Text] [Related]
56. Effects of captopril and enalapril on regional vascular resistance and reactivity in spontaneously hypertensive rats.
Richer C; Doussau MP; Giudicelli JF
Hypertension; 1983; 5(3):312-20. PubMed ID: 6188693
[TBL] [Abstract][Full Text] [Related]
57. Inhibitor of angiotensin I converting enzyme: (4R)-3-[(2S)-3-mercapto-2-methylpropanoyl]-4-thiazolidinecarboxylic acid (YS-980).
Funae Y; Komori T; Sasaki D; Yamamoto K
Biochem Pharmacol; 1980 Jun; 29(11):1543-7. PubMed ID: 6249321
[No Abstract] [Full Text] [Related]
58. Effects of YS-980, an orally active converting enzyme inhibitor, on blood pressure in normotensive and hypertensive rats.
Komori T; Yamamoto K
Jpn J Pharmacol; 1981 Jun; 31(3):401-7. PubMed ID: 6273629
[TBL] [Abstract][Full Text] [Related]
59. The present molecules of converting enzyme inhibitors.
Brunner HR; Nussberger J; Waeber B
J Cardiovasc Pharmacol; 1985; 7 Suppl 1():S2-11. PubMed ID: 2580170
[TBL] [Abstract][Full Text] [Related]
60. Role of angiotensin converting enzyme inhibitors in essential and renal hypertension. Effects of captopril and enalapril on renin-angiotensin-aldosterone, renal function and hemodynamics, salt and water excretion, and body fluid composition.
Bauer JH
Am J Med; 1984 Aug; 77(2A):43-51. PubMed ID: 6206722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
